Boston Scientific plans to conduct offering of senior notes

By Devika Patel

Knoxville, Tenn., Feb. 22 – Boston Scientific Corp. plans to price dollar-denominated senior notes (Baa2), according to a 424B2 filed with the Securities and Exchange Commission.

The notes feature a make-whole call until three months prior to maturity and then a par call.

Barclays, BofA Merrill Lynch and Citigroup Global Markets Inc. are the bookrunners.

Proceeds will be used to redeem the company’s $600 million of 2.65% notes due October 2018 and to repay short-term debt.

Boston Scientific is a medical device maker based in Marlborough, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.